GlassScriptPhysician profile
Trung H Pham
NPI 1669491999
$20,301.64
in general payments reported to CMS, 2019-2025
58 companies · $2,202 in 2025
The $2,202 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,853 · 2020: $3,244 · 2021: $3,844 · 2022: $3,087 · 2023: $2,713 · 2024: $2,359 · 2025: $2,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,120 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,120.01 |
| Education | $153.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,076.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,889.50 | 2019-2025 | Breztri, Farxiga, Tezspire |
| Glaxosmithkline, LLC. | $1,556.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,396.80 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,341.32 | 2019-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Amgen INC. | $1,341.16 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $1,092.68 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $875.76 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $792.36 | 2019-2024 | Xarelto |
| Pfizer INC. | $731.91 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $626.51 | 2021-2024 | |
| Astellas Pharma US INC | $580.15 | 2019-2025 | Veozah |
| Gilead Sciences, INC. | $496.47 | 2019-2025 | |
| Allergan, INC. | $467.94 | 2019-2020 | |
| Esperion Therapeutics, INC. | $419.28 | 2020-2025 | Nexletol |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trung Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.